Bendamustine in combination with thalidomide and prednisone in patients with refractory or relapsed multiple myeloma. preliminary results of a phase I clinical trial

被引：0
|
作者：
Pönisch, W
Rozanski, M
Leiblein, S
Goldschmidt, H
Wegner, A
Niederwieser, D
机构：
[1] Univ Leipzig, Dept Haematol Oncol, D-7010 Leipzig, Germany
[2] Ribosepharm GmbH, Munich, Germany
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
584
引用
收藏
页码：208 / 208
页数：1
相关论文
共 50 条
  • [31] Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077)
    Juliane Beck
    Andreas Schwarzer
    Dietrich Gläser
    Lars-Olof Mügge
    Jens Uhlig
    Simone Heyn
    Brigitte Kragl
    Martin Mohren
    Franz Albert Hoffmann
    Thoralf Lange
    Thomas Schliwa
    Thomas Zehrfeld
    Cornelia Becker
    Ute Kreibich
    Cornelia Winkelmann
    Thomas Edelmann
    Marc Andrea
    Marius Bill
    Madlen Jentzsch
    Sebastian Schwind
    Dietger Niederwieser
    Wolfram Pönisch
    Journal of Cancer Research and Clinical Oncology, 2017, 143 : 2545 - 2553
  • [32] Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma.
    Somlo, G
    Bellamy, W
    Zimmerman, TM
    Frankel, P
    Tuscano, J
    O'Donnell, M
    Mohrbacher, A
    Forman, S
    Chen, H
    Doroshow, J
    Gandara, D
    BLOOD, 2005, 106 (11) : 723A - 723A
  • [33] Thalidomide and dexamethasone combination for refractory multiple myeloma.
    Galani, E
    Grigoraki, V
    Kiamouris, C
    Samantas, E
    Economou, O
    Papdimitriou, C
    Gika, D
    Anagnostopoulos, N
    Dimopoulos, M
    ANNALS OF ONCOLOGY, 2000, 11 : 96 - 96
  • [34] Addition of low dose Cyclophosphamide to the combination of Thalidomide and Dexamethasone in patients with relapsed/refractory multiple myeloma.
    Di Raimondo, F
    Pennisi, A
    Buglio, D
    Fiumara, P
    Palumbo, GA
    Giustolisi, R
    BLOOD, 2003, 102 (11) : 385B - 385B
  • [35] Salvage therapy with thalidomide for patients with advanced relapsed/refractory multiple myeloma.
    Tosi, P
    Ronconi, S
    Zamagni, E
    Cellini, C
    Tura, S
    Cavo, M
    BLOOD, 2000, 96 (11) : 296B - 296B
  • [36] ENMD-0995 (S 3-APG), a novel thalidomide analogue, has promising clinical activity for patients with relapsed refractory multiple myeloma. Preliminary results of a phase I clinical trial.
    Lacy, MQ
    Dispenzieri, A
    Gertz, MA
    Wilzig, TE
    Greipp, PR
    Fonseca, R
    Lust, JA
    Kumar, S
    Zeldenrust, S
    Kyle, RA
    Snow, D
    Hayman, SR
    Sidor, CF
    Treston, AM
    Zeldis, JB
    Rajkumar, SV
    BLOOD, 2003, 102 (11) : 453A - 453A
  • [37] Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma
    Dhakal, Binod
    D'Souza, Anita
    Hamadani, Mehdi
    Arce-Lara, Carlos
    Schroeder, Katrina
    Chhabra, Saurabh
    Shah, Nirav N.
    Gauger, Katelyn
    Keaton, Taylor
    Pasquini, Marcelo
    Hari, Parameswaran
    BLOOD CANCER JOURNAL, 2019, 9 (8)
  • [38] Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma
    Berenson, James R.
    Yellin, Ori
    Bessudo, Alberto
    Boccia, Ralph V.
    Noga, Stephen J.
    Gravenor, Donald S.
    Patel-Donnelly, Dipti
    Siegel, Robert S.
    Kewalramani, Tarun
    Gorak, Edward J.
    Nassir, Youram
    Swift, Regina A.
    Mayo, Debra
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 160 (03) : 321 - 330
  • [39] Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma
    Binod Dhakal
    Anita D’Souza
    Mehdi Hamadani
    Carlos Arce-Lara
    Katrina Schroeder
    Saurabh Chhabra
    Nirav N. Shah
    Katelyn Gauger
    Taylor Keaton
    Marcelo Pasquini
    Parameswaran Hari
    Blood Cancer Journal, 9
  • [40] Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma
    Poenisch, Wolfram
    Bourgeois, Malvina
    Moll, Barbara
    Heyn, Simone
    Jaekel, Nadja
    Wagner, Ina
    Rohrberg, Robert
    Hurtz, Hans-Juergen
    Schmalfeld, Marion
    Assmann, Michael
    Edelmann, Thomas
    Mohren, Martin
    Hoffmann, Franz Albert
    Becker, Cornelia
    Schwarzer, Andreas
    Schoenfelder, Uta
    Zehrfeld, Thomas
    Hensel, Gerald
    Loeschcke, Kerstin
    Krahl, Rainer
    Al Ali, Haifa
    Niederwieser, Dietger
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (03) : 499 - 508
12345